Nokia Corporation - Managers' transactions (Hotard)
Person subject to the notification requirementName: Hotard, Justin Position: Chief Executive Officer
Issuer: Nokia CorporationLEI: 549300A0JPRWG1KI7U06
Notification type: INITIAL NOTIFICATIONReference number: 110867/5/4____________________________________________
Transaction date: 2025-06-03Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009000681Nature of the transaction: ACQUISITION
Transaction details(1): Volume: 609 274 Unit price: 4.6301 EUR
Aggregated transactions(1): Volume: 609 274 Volume weighted average price: 4.6301 EUR
About NokiaAt Nokia, we create technology that helps the world act together.As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs, which is celebrating 100 years of innovation.
With truly open architectures that seamlessly integrate into any ecosystem, our high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with us to create the digital services and applications of the future.
Inquiries:Nokia CommunicationsPhone: +358 10 448 4900Email: press.services@nokia.comMaria Vaismaa, Global Head of External CommunicationsNokiaInvestor RelationsPhone: +358 931 580 507Email: investor.relations@nokia.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Aumann AG (AUUMF) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aumann AG (AUUMF) maintained a strong profitability with a double-digit margin of 10.5% despite a challenging market environment. The company has a solid financial foundation with EUR 105 million in net cash, allowing flexibility to respond to market opportunities. Aumann AG (AUUMF) is strategically expanding its focus beyond the automotive industry into growth areas like aerospace, defense, and life sciences. The company is a technology leader in the e-mobility sector, providing comprehensive production solutions for electric vehicle components. Aumann AG (AUUMF) is benefiting from macroeconomic trends such as demographic changes and labor shortages, which drive demand for automation solutions. Negative Points Revenue for the first half of 2025 decreased by 23% compared to the previous year, aligning with the company's forecasted decline. Order intake dropped by 31% year over year, reflecting a challenging market environment and subdued investment climate in the automotive sector. The order backlog decreased significantly by 44% year over year, indicating potential future revenue challenges. The e-mobility segment saw a 21% decline in revenue, and order intake was 39% lower than the previous year. Market uncertainties, including geopolitical tensions and tariff dynamics, continue to impact the company's performance and investment climate. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AUUMF. Q: Can you provide details on the composition of the margins of your order intake and whether the weaker environment is affecting those margins? A: CEO Sebastian Roll explained that maintaining margins in the current environment is challenging, but they are managing to do so by securing better prices from suppliers. The order backlog even shows a slightly better margin situation, which helps maintain the expected 8 to 10% EBITDA margins. Q: How are China's rare earth magnet export controls affecting project timing with your customers? A: CEO Sebastian Roll noted that the export controls are prompting discussions with customers about alternative solutions, such as using winded rotors in traction cars. This shift could benefit Aumann as they provide precise winding solutions, which are becoming more desirable. Q: What is the impact of the current market environment on your revenue and profitability guidance for 2025? A: CFO Jan Henrik Pollitt stated that despite a challenging market environment, Aumann expects a decline in revenue to between 210 and 230 million for 2025. However, they anticipate maintaining a solid EBITDA margin of 8 to 10% due to a strong order backlog and flexible company structure. Q: How is Aumann's next automation segment performing, and what are the strategic growth areas? A: CEO Sebastian Roll highlighted that the next automation segment is growing, with rising order intake. Strategic growth areas include aerospace, clean tech, and life sciences, driven by increasing demand and investment in these sectors. Q: What are the key factors contributing to Aumann's strong operational performance despite lower revenues? A: CFO Jan Henrik Pollitt attributed the strong operational performance to strict cost management, capacity adjustments, and a good quality order backlog. These factors have helped maintain a double-digit EBITDA margin despite a 23% decline in revenue. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Adyen NV (ADYYF) (H1 2025) Earnings Call Highlights: Strong Growth in Unified Commerce and ...
Net Revenue: EUR 1.1 billion, representing 21% growth on a constant currency basis. EBITDA Growth: 28% increase, with EBITDA margins reaching 50%. Regional Growth: MEIA region grew by 21%, North America by 20%. Digital Segment Growth: 10% increase in net revenues. Unified Commerce Growth: 31% increase in net revenues. Platforms Growth: 55% increase, with 32 platforms processing over a billion euros annually. Warning! GuruFocus has detected 2 Warning Signs with ADYYF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Adyen NV (ADYYF) reported a resilient first half of 2025 with net revenues growing to approximately EUR1.1 billion, marking a 21% growth on a constant currency basis. The company saw strong growth in its unified commerce segment, with net revenues increasing by 31%, driven by strength in retail, food and beverage, hospitality, and entertainment verticals. Platforms segment was the fastest-growing pillar, with a 55% increase in net revenues, highlighting the success of Adyen's strategy to support platforms in embedding payments. Adyen NV (ADYYF) continues to innovate, with successful product launches like Intel payment routing and Uplift, which have seen high uptake and are helping optimize authorization rates and reduce fraud. The company is expanding its share of wallet with existing customers and adding new customer logos, indicating strong future growth potential. Negative Points Adyen NV (ADYYF) faced negative impacts from macroeconomic factors, including a strong euro and tariffs affecting merchants in the APAC region trading into the US. The growth of Adyen's own customer base was lower than expected, impacting overall growth projections. The company experienced a deceleration in growth from the second half of last year to the first half of this year by about 6 percentage points. Adyen NV (ADYYF) had to adjust its full-year guidance due to the impact of tariffs and macroeconomic challenges, particularly affecting a subset of APAC merchants. Despite strong growth in certain segments, the overall market volume growth was not as high as anticipated, affecting revenue expectations. Q & A Highlights Q: Could you reassure us on the scale of the exposure to the cohort of merchants in Asia selling into the US, and what assumptions have you made for the second half of the year regarding this impact? A: Ethan Tandowsky, CFO, explained that the impact from this subset of customers was significant, with growth approximately 2% lower in Q2 due to this issue. They expect this impact to continue through the second half, which is why they anticipate similar growth rates in H2 as seen in H1. Q: Can you provide more details on the modularized services and how they are resonating with customers? A: Ingo Uytdehaage, Co-CEO, highlighted that modularization is crucial for meeting customer needs. The platform's flexibility allows customers to consolidate services like risk management with Adyen, which can lead to increased acquiring over time. This strategy is aligned with customer stability and growth. Q: How do you see the second half of the year playing out, especially considering the current macroeconomic backdrop? A: Ethan Tandowsky, CFO, stated that they expect second-half net revenue growth to be similar to the first half. The focus remains on expanding share of wallet with existing customers and adding new logos. They are confident in their growth opportunities despite lower market volume growth than initially expected. Q: Can you elaborate on the impact of tariffs and macroeconomic trends on your business? A: Ethan Tandowsky, CFO, noted that the tariff impact was primarily seen in Q2 and is expected to persist through the second half. While macroeconomic trends are mixed with share of wallet gains, the most significant impact was from the APEC merchants, which they have quantified. Q: What are the drivers of growth in LatAm and APAC, and how do you view the potential for stablecoins? A: Ethan Tandowsky, CFO, mentioned strong growth in LatAm due to investments in Brazil and Mexico, while APAC growth is driven by long-term plays in Japan and India. Ingo Uytdehaage, Co-CEO, added that stablecoins could be integrated if customer demand arises, particularly for moving money efficiently in high-inflation scenarios. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Valneva SE (INRLF) (H1 2025) Earnings Call Highlights: Robust Revenue Growth Amid Operational ...
Total Revenue: EUR97.6 million, a 37.8% increase from EUR70.8 million in the first half of 2024. Product Sales: EUR91 million, up 33.3% from EUR68.3 million in the first half of 2024. IXIARO Sales: EUR54.7 million, a 30.6% increase year-over-year. DUKORAL Sales: EUR17.4 million, a 16.4% increase year-over-year. IXCHIQ Sales: EUR7.5 million, up from EUR1 million in the first half of 2024. Gross Margin (excluding IXCHIQ): 59.2%, up from 47.7% in the prior year. IXIARO Gross Margin: 65.5%, compared to 57.5% in the first half of 2024. DUKORAL Gross Margin: 52.9%, compared to 34.8% last year. Operating Loss: EUR16.8 million, compared to an operating profit of EUR46.7 million last year. Adjusted EBITDA: Minus EUR6 million, compared to a positive EUR56.2 million last year. Cash Position: EUR161.3 million as of June 30, 2025. Cash Used in Operations: EUR10.9 million, down from EUR66.3 million in the first half of 2024. 2025 Financial Guidance: Product sales of EUR170 million to EUR180 million; total revenues of EUR180 million to EUR190 million. Warning! GuruFocus has detected 8 Warning Signs with INRLF. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Valneva SE (INRLF) achieved significant year-over-year revenue growth, reaching close to EUR100 million in the first half of 2025. The company maintained a strong cash position of over EUR160 million, indicating effective cash management and reduced operating cash burn. Valneva SE (INRLF) secured additional marketing authorizations for its chikungunya vaccine, IXCHIQ, in the UK, Brazil, and Europe, expanding its market reach. The Lyme disease vaccine candidate, VALOR, is progressing as planned, with Pfizer aiming for regulatory submissions in 2026. The company reported positive Phase III pediatric safety and immunogenicity results for IXCHIQ, reinforcing its potential in the market. Negative Points Valneva SE (INRLF) reported an operating loss of EUR16.8 million in the first half of 2025, compared to an operating profit in the previous year. The company experienced adverse foreign currency fluctuations, impacting revenues by EUR500,000. Research and development expenses increased, driven by costs related to the Shigella vaccine candidate. The company faced temporary restrictions on its chikungunya vaccine, IXCHIQ, due to safety concerns, impacting market uptake. Valneva SE (INRLF) anticipates an acceleration of R&D costs in the second half of 2025, which could further impact financial performance. Q & A Highlights Q: Regarding the 40,000 doses sold to the French government, should we expect any additional revenue recognition in Q3? Also, could you share your perspective on demand scenarios for IXCHIQ through year-end, considering the evolving CHIKV outbreak in the Indian Ocean and China? A: The 40,000 doses were all shipped in the first half of the year, and the revenue was fully recognized in that period. Regarding demand scenarios, we are in contact with governments where outbreaks are occurring. We have no supply constraints and sufficient material available, but it's too early to state where and how we will respond. We aim to stay in control over potential vaccination campaigns given past experiences. Q: For the Lyme vaccine, could you provide insight on how the reporting of data readouts will transpire at year-end? Will the disclosure only report top-line data, or can we expect detailed results? A: The reporting of Phase III results is under Pfizer's responsibility. We expect data readout in two steps: a report on top-line data, primarily efficacy numbers, followed by communication on other endpoints. All data should be out by the end of the first quarter, supporting regulatory submissions around mid-next year. Q: Could you elaborate on what might trigger an acceleration in IXCHIQ sales uptake within the traveler market? Are you still in discussions with the U.S. for potential stockpiling? A: The uncertainty from safety investigations has impacted market uptake. However, the vaccine's profile, especially as a live-attenuated single-shot vaccine, has advantages for outbreak preparedness. We expect new momentum now that restrictions are lifted and investigations concluded. Discussions on stockpiling will hopefully resume later this year. Q: On the Lyme and VALOR trial, suggests a primary completion date of December 26. Are you confident that Phase III headline data will come in 2025, or could it spill into 2026? What is the bar for success in this trial? A: The primary completion date includes safety follow-up periods. Case counts will continue until the end of October, followed by Pfizer's case adjudication and database cleaning. The timing of data readout is not in our control, but Pfizer reaffirms submission timelines. There is no specific communicated bar for approval, but we expect non-inferiority or superiority compared to past vaccines. Q: What should we expect in terms of financial impact from the distribution agreement with CSL? A: The commercial terms with CSL are similar to our previous agreement, so we do not expect an immediate difference in prospects around Germany. However, as CSL gears up, there may be potential upside in the mid- to long term. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
